Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-09-02 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于增选非独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the nomination and election of a non-independent director to the company's board. It includes details about the nominee's background, qualifications, and compliance with regulatory requirements. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and focused on this specific announcement, confirming it is not a full report or other type of filing.
2021-09-02 Chinese
上海荣正投资咨询股份有限公司关于贝达药业股份有限公司2021年限制性股票激励计划（草案）之财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2021 Restricted Stock Incentive Plan of Betta Pharmaceuticals Co., Ltd. It contains detailed information about the stock incentive plan, including the scope of incentive recipients, number of restricted stocks granted, effective period, grant price, conditions for granting and vesting, and the advisor's opinions on the plan's compliance with laws and regulations. The document is lengthy (15,000 characters) and contains substantive financial and operational details about the stock incentive plan. It is not a simple announcement or a certification letter but a detailed advisory report on a capital-related plan. Given the content focuses on a stock incentive plan, which is a form of capital/financing update, the most appropriate classification is Capital/Financing Update (CAP).
2021-09-02 Chinese
独立董事关于2021年限制性股票激励计划公开征集委托投票权的报告书
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a report by an independent director regarding the public solicitation of proxy voting rights for a 2021 second extraordinary general meeting of shareholders. It details the solicitation process, voting instructions, and legal compliance related to a restricted stock incentive plan. It is not a financial report, earnings release, or management discussion. It is not a notice of voting results but rather a solicitation for proxy votes. The document is a formal report related to governance and shareholder voting procedures, specifically about proxy solicitation for a shareholder meeting. Therefore, it fits best under Proxy Solicitation & Information Statement (PSI). The document length is about 5,457 characters, which is substantive and contains detailed procedural information, not just an announcement or a brief notice.
2021-09-02 Chinese
浙江天册律师事务所关于贝达药业股份有限公司2021年限制性股票激励计划的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the 2021 restricted stock incentive plan of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It extensively discusses the legal compliance, conditions, scope, stock quantities, pricing, vesting, and other regulatory aspects of the stock incentive plan. The document references relevant laws, regulations, and company bylaws, and provides a professional legal opinion on the plan's legality and compliance. It is not a financial report, earnings release, or management discussion, nor is it a simple announcement or certification. It is a legal opinion related to a capital/financing activity (stock incentive plan issuance). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-09-02 Chinese
2021年限制性股票激励计划实施考核管理办法
Remuneration Information Classification · 95% confidence The document is titled as the '2021 Restricted Stock Incentive Plan Implementation Assessment Management Measures' for Betta Pharmaceuticals Co., Ltd. It details the assessment criteria, management structure, performance targets, and procedures related to the company's restricted stock incentive plan for the years 2021-2025. The content focuses on governance and management of an equity incentive plan rather than financial results, audit opinions, or shareholder meeting materials. It is a formal internal governance document related to compensation and incentive mechanisms, which aligns with Remuneration Information filings. The document is 3840 characters long, which is relatively short and detailed, not an announcement or summary. Therefore, it is best classified as Remuneration Information (DEF 14A) rather than a general governance report or regulatory filing.
2021-09-02 Chinese
第三届监事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Betta Pharmaceuticals Co., Ltd. regarding the approval of proposals related to the 2021 restricted stock incentive plan, its implementation assessment management measures, and the verification of the incentive object list. It includes details about the meeting, voting results, and references to related documents disclosed elsewhere. The document is a formal announcement of board/management decisions and approvals, not a full report or financial statement. It does not contain financial data or detailed management discussion but rather governance and supervisory board meeting resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on meeting resolutions, not a full report or regulatory filing.
2021-09-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.